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Objectives: The purpose of this analysis was to estimate how higher persistence 
in RRMS patients treated with interferon beta 1-a and its electronic injection device 
(Rebismart®) affects the rate of escalation to 2nd line therapies. MethOds: A 2-year, 
decision-analytic model was developed to track a hypothetical cohort of 1,000 RRMS 
patients initiating treatment with either interferon beta 1-a and Rebismart® or 
another 1st line self-injectable disease modifying drug (DMD). The model calculated 
the expected probability of escalating to 2nd line therapy, which was defined as either 
Gilenya® or Tysabri®. Persistence curves were estimated from a real-world dataset 
collected from the UK NHS where at 2 years Rebismart® users had 83% persistence vs. 
60% in non- Rebismart® users. A market research study was utilized to determine the 
treatment pathways for non-persistent patients, where 39% transitioned to another 
1st line DMD; 21% abandoned therapy and 40% escalated to 2nd line therapies. One-
way sensitivity analyses (OWSAs) varied the probability of non-persistent 1st line 
patients escalating to 2nd line therapies from 5% to 100%. Results: The model esti-
mated that over two years 5.4% of patients on the Rebismart® device are expected to 
escalate to 2nd line therapy, while 18.3% of patients that initiated treatment on other 
DMDs are expected to escalate. At the lower bound of the OWSA, 0.68% of patients are 
expected to escalate on Rebismart®, vs. 2.3%; while at the upper bound of the OWSA, 
13.3% of Rebismart® patients are expected to escalate vs. 42.7%. cOnclusiOns: 
Higher persistence rates in RRMS patients initiating treatment with interferon beta 
1-a and the Rebismart® electronic device are expected to result in fewer escalations 
to 2nd line therapies relative to other self-injectable DMDs.
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Objectives: To assess the relative efficacy and safety of modified-release levodopa 
(IPX066), controlled-release levodopa and add-on therapy to immediate-release 
levodopa (including dopamine agonists, monoamine oxidase-B inhibitors (MAOBI), 
and catechol-O-methyl transferase inhibitors (COMTI)) using network meta-analy-
sis (NMA). MethOds: A systematic literature search was conducted in MEDLINE, 
MEDLINE In-Process, EMBASE, Cochrane Database of Systematic Reviews, Cochrane 
Central Register of Controlled Trials, DARE and HTA. A random effects NMA was used 
to determine the relative efficacy and safety of treatments on off-time reduction, 
three Unified Parkinson’s Disease Rating Scale (UPDRS) scores, patient withdrawals, 
and six adverse events in WinBUGS. An additional analysis was conducted to assess 
treatment class effects. Node-splitting approach was used to assess the assumption of 
consistency when direct and indirect evidence was combined. Results: Forty-three 
trials with 9,453 patients were identified. Immediate-release levodopa plus prami-
pexole produced the greatest reduction in off-time relative to immediate-release 
levodopa plus placebo (-1.71 hours a day; 95% CrI: -2.11, -1.35), followed by IPX066 
(-1.40; 95% CrI: -2.19, -0.67). The greatest improvement on UPDRS ADL score was given 
by add-on ropinirole (-2.33 points; 95% CrI: -3.53, -1.06); on UPDRS motor and total 
score was given by add-on pramipexole (-5.88 points; 95% CrI: -7.22, -4.63 and -10.09 
points; 95% CrI: -13.75, -6.56, respectively). Dyskinesia was increased with IPX066 and 
adjuvant therapy classes except for MAOBIs. Patient withdrawals were also increased 
with IPX066 and controlled-release levodopa. cOnclusiOns: The NMA showed that 
all treatments except controlled-release levodopa were associated with a statistically 
significant reduction in off-time. Dopamine agonist class as adjunctive to levodopa 
therapy had the greatest reduction. IPX066 was broadly comparable with add-on 
dopamine agonists on off-time reduction, and comparable with add-on MAOBIs and 
COMTIs on UPDRS scores. However, the treatments were associated with an increase 
in the risk of having dopaminergic side effects, particularly dyskinesia.
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Objectives: To describe caregivers’ Health Related Quality of Life (HRQoL), burden, 
anxiety and depression and their relation with patients’ symptoms in Parkinson 
disease (PD). MethOds: A descriptive, observational, longitudinal design in PD 
patients and their caregivers of ELEP study (2006-2010), in Spain. Information 
collected during 3 month per year for 4 years, included sociodemographic char-
acteristics, motor symptoms (SCOPA-Motor) and HRQoL (EQ-5D: index and VAS) 
from PD patients and burden (Zarit’s CBI), anxiety (HADS-A), depression (HADS-D) 
and HRQoL from their caregivers. Linear mixed models were performed to assess 
the relation between caregivers’ burden with the patients’ motor symptoms and 
HRQoL. Results: 174 PD patients, mean age: 63±11, 50% male, PD duration: 8±6 
years; 173 caregivers, 66.5% female, mean number of years taking care of patients: 
6±5, were included. Patients’ SCOPA-Motor varied from 39.3±8.4 in year 1 to 42.5±9.5 
in year 4; EQ-5D index and VAS from 0.7±0.3 and 63.7±20.3 to 0.6±0.3 and 60.3±17.9, 
respectively. Caregivers’ ZCBI varied from 17.6±12.6 to 20.0±14.8; EQ-5D index 
remained unchanged at 0.8±0.2, while VAS varied from 73.7±18.6 to 75.0±16.2; 
HADS-D scores changed between 4.0±3.7 and 4.4±4.3, and HADS-A from 6.7± 3.8 
to 6.9±4.3. Linear mixed models revealed that caregivers’ anxiety and depression 
negatively influenced their own perception of disease burden [HADS-A, Estimated 
coefficient (EC): 1.02 (SE: 0.15), p< 0.000; HADS-D, EC: 1.19 (SE: 0.17), p< 0.000]. Patients’ 
motor symptoms predicted worse caregiver burden [SCOPA-Motor EC: 0.22 (SE: 0.09), 
p= 0.014]. Decline in patients HRQoL implied a higher caregiver burden [EQ-5D index 
EC: -5.56 (SE: 2.70), p< 0.041]. cOnclusiOns: PD patients’ moderate motor symp-
toms and fair HRQoL worsened over time as did caregivers’ anxiety and disease 
automated Optical Character Recognition (OCR) system. Patients younger than 18 
years of age, diagnosed with Paget’s disease or purchasing pamidronic or zoledrnic 
acid due to cancer were excluded. Registry entry date was defined as the first medi-
cal event consistent with any of inclusion and all exclusion criteria. Results: We 
identified 118,141 patients with osteoporosis, with a point prevalence of 19% in 2013 
among members aged 50+, and an average incidence of approximately 6,300 cases 
a year. Average age at registry entry was 61 y/o for women and 66 y/o for men. 66% 
of the patients had more than one qualifying criteria. 28% of the registry patients 
were never treated. cOnclusiOns: The methods and results described may provide 
a model for the development of an important tool to assess the substantial burden 
of osteoporosis and to monitor the quality of care over time.
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Objectives: The use of PPIs to reduce the risk of upper GI events caused by 
NSAIDs is well documented. The aim of this study was to understand whether 
newly diagnosed patients with OA, RA or AS not previously exposed to PPIs, receive 
a gastro-protectant with their NSAID treatment at initiation or follow up in a 
primary care setting. MethOds: We analyzed data from primary care Electronic 
Medical Records in Ontario, Canada. Patients ≥ 18 years, who were new users of 
NSAIDs, NSAID plus a PPI, a fixed combination of diclofenac and misoprostol, or 
Celecoxib between January 1st 2010 and May 31st 2012 were selected. Patients must 
have had a diagnosis for OA, RA, or AS within 6 months of treatment initiation, 
but no diagnosis in the year prior. Patients were followed for 6 months to assess 
for subsequent PPI prescription. Patients prescribed a PPI in the last 12 months 
were excluded. Results were compared to Canadian longitudinal pharmacy 
data. Results: There were 692 patients included, 56% females and a mean age of 
44 years (SD 15). Naproxen was the most commonly used treatment (41%), followed 
by diclofenac (26%), celecoxib (14%) and diclofenac with misoprostol (19%). PPIs 
were added at treatment initiation in 2.5% of naproxen patients, 1.7% of diclofenac 
patients and 3.7% of patients with fixed combination of diclofenac and misopros-
tol. PPI prescription patterns within 6 months were similar and consistent with 
patterns observed in the Canadian longitudinal pharmacy data. cOnclusiOns: 
Results suggest that primary care physicians in Canada do not prescribe PPIs 
with NSAIDs at or within 6 months after NSAID initiation. Limitations include 
small sample size and young patient cohort. Further studies are required to bet-
ter understand the impact of low PPI concomitant use with NSAIDs, especially in 
older patients or those at a higher risk of GI events.
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Objectives: This study aimed to investigate and compare the gastrointestinal (GI) 
risk factors and treatment patterns of rheumatoid arthritis (RA) and osteoarthritis 
(OA) patients in real clinical practice of Korea. MethOds: This was a nationwide, 
cross-sectional study of patients taking non-steroidal anti-inflammatory drugs 
(NSAID, either non-selective or selective COX-2 inhibitor (COX2i)) from 20 hospitals 
between December 2012 and September 2013. Total 1,896 patients who were ≥ 20 
years old (RA: 981 OA: 915) and were taking NSAID at least 1 month were enrolled. 
Data were collected through medical chart review and patients survey. The GI risk 
factors included NSAID duration (≥ 3 months), high-dose of NSIAD use, drinking, 
smoking, comorbid disease, aspirin use, anticoagulant (warfarin) use, steroid use, 
Helicobacter pylori infection, experience of GI event (i. e. GI bleeding or ulcer). The 
treatment patterns were identified as non-selective NSAID (ns-NSAID) or COX2i 
with/without gastroprotective agents respectively. Results: In RA, proportion of 
patients taking NSAID≥ 3 months, smoker and steroid users were higher than in 
OA patients (p< . 0001). In OA, proportion of patients who have comorbid disease 
and take aspirin were higher than in RA patients (p< . 0001). The rest of the GI 
risk factors were present as a similar proportion in both groups. The percentage 
of treatment with COX2i (RA: 54.3% vs OA: 44.2%, p< . 001) and gastroprotective 
agents (RA: 83.0% vs OA: 78.3%, p= . 009) in RA patients was higher than that in 
OA patients. In older aged patients (age≥ 60) in both groups, there was tendency 
to get more treatment of COX2i (RA: 60.9%, OA: 50.2%) compared to ns-NSAID. 
Interestingly, as patients get more numbers of GI risk factors, there seemed to get 
more proportions of ns-NSAIDs users in both RA and OA patients. cOnclusiOns: 
The proportion of GI risk factors found in OA patients was comparable to that 
in RA patients. There was a tendency to show preferential ns-NSAID treatment 
pattern rather than COX2i especially in the presence of multiple GI risk factors 
in arthritis patients.
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